Compare
Gilead Sciences vs Eli Lilly and
MonkScore ranges and fundamentals, side by side
Key facts
Gilead Sciences and Eli Lilly and: key facts
- In fiscal 2025, Gilead Sciences, Inc. reported revenue of $29.4B and net income of $8.5B.
- In fiscal 2025, Eli Lilly and Company reported revenue of $65.2B and net income of $20.6B.
- Gilead Sciences, Inc.'s revenue grew 1.9% a year from fiscal 2021 to fiscal 2025.
- Eli Lilly and Company's revenue grew 23.2% a year from fiscal 2021 to fiscal 2025.
- Gilead Sciences, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- Eli Lilly and Company's free cash flow was positive in 4 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Gilead Sciences, Inc. reported revenue of $31.0B and net income of -$3.9B.
- In the twelve months to 30 September 2026, Eli Lilly and Company reported revenue of $86.5B and net income of $27.6B.
Side by side
Gilead Sciences and Eli Lilly and, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Gilead Sciences, Inc.NASDAQ:GILD | Eli Lilly and CompanyNYSE:LLY |
|---|---|---|
| MonkScore | ||
| MonkScore range | 90–100as of October 2026 | 90–100as of October 2026 |
| Sector rank | 39 of 628 in Healthcare | 22 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Latest fiscal year | ||
| Revenue | $29.4BFY 2025 | $65.2BFY 2025 |
| Net income | $8.5BFY 2025 | $20.6BFY 2025 |
| Free cash flow | $9.5BFY 2025 | $9.0BFY 2025 |
| Operating cash flow | $10.0BFY 2025 | $16.8BFY 2025 |
| Total debt | $24.9BFY 2025 | $42.5BFY 2025 |
| Cash | $7.6BFY 2025 | $7.2BFY 2025 |
| Last 12 months | ||
| Revenue | $31.0Bto 30 September 2026 | $86.5Bto 30 September 2026 |
| Net income | -$3.9Bto 30 September 2026 | $27.6Bto 30 September 2026 |
| Free cash flow | $14.0Bto 30 September 2026 | $19.7Bto 30 September 2026 |
| Operating cash flow | $14.5Bto 30 September 2026 | $30.6Bto 30 September 2026 |
| Total debt | $26.2Bto 30 September 2026 | $49.5Bto 30 September 2026 |
| Cash | $6.4Bto 30 September 2026 | $4.9Bto 30 September 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.